[PDF][PDF] Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with …
M Herold, A Haas, S Srock, S Neser… - Journal of Clinical …, 2007 - academia.edu
M Herold, A Haas, S Srock, S Neser, KH Al-Ali, A Neubauer, G Dölken, R Naumann…
Journal of Clinical Oncology, 2007•academia.eduPurpose Rituximab has been shown to be active in follicular lymphoma (FL), both as
monotherapy and in combination with chemotherapy. We conducted a randomized trial
comparing mitoxantrone, chlorambucil, and prednisolone (MCP) chemotherapy plus
rituximab with MCP alone.
monotherapy and in combination with chemotherapy. We conducted a randomized trial
comparing mitoxantrone, chlorambucil, and prednisolone (MCP) chemotherapy plus
rituximab with MCP alone.
Purpose
Rituximab has been shown to be active in follicular lymphoma (FL), both as monotherapy and in combination with chemotherapy. We conducted a randomized trial comparing mitoxantrone, chlorambucil, and prednisolone (MCP) chemotherapy plus rituximab with MCP alone.
academia.edu